Literature DB >> 102228

Increased risk of lymphoma in sicca syndrome.

S S Kassan, T L Thomas, H M Moutsopoulos, R Hoover, R P Kimberly, D R Budman, J Costa, J L Decker, T M Chused.   

Abstract

The risk of cancer was ascertained in 136 women with sicca syndrome followed at the National Institutes of Health (NIH). Seven patients developed non-Hodgkin's lymphoma from 6 months to 13 years after their first admission to NIH. This was 43.8 times (P less than 0.01) the incidence expected from the rates of cancer prevailing among women of the same age range in the general population during this time. In addition, three cases of Waldenström's macroglobulinemia occurred in this study group. Eight patients developed cancers other than lymphoma, similar to the number expected based on the rates prevailing in the general population. Patients with a history of parotid enlargement, splenomegaly, and lymphadenopahy had an increased risk of lymphoma. These clinical conditions did not appear to be early manifestations of undiagnosed lymphoma but rather seemed to identify a subgroup of patients with sicca syndrome with marked lymphoid reactivity, who had a particularly high risk of subsequently developing lymphoma.

Entities:  

Mesh:

Year:  1978        PMID: 102228     DOI: 10.7326/0003-4819-89-6-888

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  178 in total

Review 1.  Therapy of Sjögren's syndrome.

Authors:  N M Moutsopoulos; H M Moutsopoulos
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

3.  Long-term course of tear gland function in patients with keratoconjunctivitis sicca and Sjögren's syndrome.

Authors:  A A Kruize; O P van Bijsterveld; R J Hené; P C de Wilde; T E Feltkamp; L Kater; J W Bijlsma
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

4.  'Lupus lymphadenitis' simulating a strangulated femoral hernia in a patient with mixed connective tissue disease.

Authors:  N J Simmonds; B I Hoffbrand
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

5.  Non-Hodgkin's lymphoma in rheumatoid arthritis.

Authors:  D Porter; R Madhok; H Capell
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

6.  Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome.

Authors:  Bum-Su Choung; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-03-17       Impact factor: 2.631

Review 7.  Tubulointerstitial nephritis-induced hypophosphatemic osteomalacia in Sjögren's syndrome: a case report and review of the literature.

Authors:  Yan Geng; Youlu Zhao; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2017-07-20       Impact factor: 2.980

Review 8.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 9.  Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells.

Authors:  X Mariette
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

10.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.